NeoGenomics Q3 EPS $0 Beats $(0.07) Estimate, Sales $152.00M Beat $141.65 Estimate
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics reported Q3 earnings per share (EPS) of $0, beating the estimated loss of $0.07. The company's sales also surpassed estimates, coming in at $152 million against the expected $141.65 million.
November 06, 2023 | 9:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics outperformed Q3 estimates, which could lead to a positive market reaction and potential short-term increase in the company's stock price.
NeoGenomics reported better than expected Q3 results, with both EPS and sales beating estimates. This positive financial performance could make the company's stock more attractive to investors, potentially leading to an increase in demand and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100